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ABSTRACT In 2019, the WHO tuberculosis (TB) treatment guidelines were updated
to recommend only limited use of streptomycin, in favor of newer agents or amika-
cin as the preferred aminoglycoside for drug-resistant Mycobacterium tuberculosis.
However, the emergence of resistance to newer drugs, such as bedaquiline, has
prompted a reanalysis of antitubercular drugs in search of untapped potential. Using
211 clinical isolates of M. tuberculosis from South Africa, we performed phenotypic
drug susceptibility testing (DST) to aminoglycosides by both critical concentration
and MIC determination in parallel with whole-genome sequencing to identify known
genotypic resistance elements. Isolates with low-level streptomycin resistance medi-
ated by gidB were frequently misclassified with respect to streptomycin resistance
when using the WHO-recommended critical concentration of 2 g/ml. We identified
29 M. tuberculosis isolates from South Africa with low-level streptomycin resistance
concomitant with high-level amikacin resistance, conferred by gidB and rrs 1400, re-
spectively. Using a large global data set of M. tuberculosis genomes, we observed 95
examples of this corresponding resistance genotype (gidB-rrs 1400), including identi-
fication in 81/257 (31.5%) of extensively drug resistant (XDR) isolates. In a phyloge-
netic analysis, we observed repeated evolution of low-level streptomycin and high-
level amikacin resistance in multiple countries. Our findings suggest that current
critical concentration methods and the design of molecular diagnostics need to be
revisited to provide more accurate assessments of streptomycin resistance for gidB-
containing isolates. For patients harboring isolates of M. tuberculosis with high-level
amikacin resistance conferred by rrs 1400, and for whom newer agents are not avail-
able, treatment with streptomycin may still prove useful, even in the face of low-
level resistance conferred by gidB.
KEYWORDS Mycobacterium tuberculosis, aminoglycosides, drug resistance
mechanisms, multidrug resistance, tuberculosis, whole-genome sequencing
Despite recent advances, tuberculosis (TB) remains the number one infectious killerworldwide (1). The ongoing global epidemic of drug-resistant TB and limited
effective treatment regimens for drug-resistant Mycobacterium tuberculosis have re-
sulted in significant morbidity and mortality (1). Recognition of the inadequacy of the
current antitubercular drug development pipeline, and the emergence of resistance to
new drugs—including bedaquiline (2–9), delaminid (3, 4), clofazimine (5, 7), and
linezolid (6)— has prompted a reanalysis of the existing arsenal of antitubercular drugs
in search of untapped potential. Streptomycin may be one such underutilized drug.
Discovered in 1944, streptomycin, an injectable streptidine aminoglycoside antibi-
otic, was the first antimicrobial agent with proven activity against M. tuberculosis. In
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conjunction with isoniazid and para-aminosalicylic acid (PAS), streptomycin formed
part of the first multidrug combination chemotherapy for TB, introduced in 1952. Its
initial widespread use led to the early emergence of streptomycin resistance, which
subsequently limited its clinical utility. Streptomycin remained an integral component
of first-line TB therapy until the 1980s, and its empirical use in retreatment TB regimens
was recommended until recently (10).
While the majority of the molecular determinants of aminoglycoside resistance are
known, commercial diagnostic tests that assay for genotypic streptomycin resistance
are lacking. Resistance to streptomycin does not contribute to the definition of exten-
sively drug resistant (XDR) TB, which is defined as multidrug-resistant (MDR) isolates
with additional resistance to quinolones and other injectable agents (amikacin, kana-
mycin) (11). Streptomycin is currently classified as a group C second-line agent for use
in longer MDR-TB regimens (10), which are recommended in limited circumstances
only. While XDR isolates are frequently cross-resistant to second-line injectable agents,
there may be untapped potential for continued use of streptomycin for low-level
resistance.
In our large collection of M. tuberculosis isolates from South Africa, we characterized
aminoglycoside-resistance phenotypes in conjunction with whole-genome sequencing
to identify patterns of aminoglycoside resistance. Subsequently, we used a global data
set of over 5,000 M. tuberculosis genomes to assess the occurrence of genotypic
low-level streptomycin resistance concomitant with high-level amikacin resistance
worldwide.
RESULTS
Using 211 sequenced clinical isolates of M. tuberculosis from South Africa (Table S2
in the supplemental material), we performed critical concentration testing for strepto-
mycin and kanamycin, and observed incomplete cross-resistance between these two
aminoglycosides (Table S3). Amikacin critical concentration was not performed due to
anticipated near complete cross-resistance with kanamycin (12), which was confirmed
by our MIC testing (Fig. S1). Using genomic sequences for these 211 isolates, we sought
known drug resistance markers for these aminoglycoside drugs. A total of 140 isolates
were found to have genotypic markers of streptomycin resistance, with mutations in
rpsL, rrs (non-1400), and gidB, whereas 50 isolates had mutations in rrs 1400, which
confers high-level resistance to both amikacin and kanamycin (Table 1). Two isolates
TABLE 1 Distribution of resistance-associated mutations in a South African data seta
Drug Gene Polymorphismb Number of isolates
Streptomycin rpsL K43R 31
K88R 8
rrs (non-1400) 513 7
516 6
907 1
gidB nt 62, del 1 bp 1
nt 103, del 1 bp 1
nt 108, del 1 bp 3
nt 116, del 1 bp 3
nt 282, del 130 bp 78




Kanamycin/amikacin rrs 1400 50
Kanamycin eis promoter 14 2
aOf the 211 South African isolates, 140 were found to have genotypic streptomycin resistance with
mutations in rpsL, rrs (non-1400), and gidB, as detailed in the table. Fifty strains were found to have
genotypic amikacin/kanamycin resistance with mutations in rrs 1400, and two isolates had kanamycin
resistance with an eis promoter mutation.
bnt, nucleotide; del, deletion; bp, base pairs.
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contained mutations in the promoter region of eis, which confers resistance to kana-
mycin, but not to streptomycin or amikacin. Co-occurrence of streptomycin and
amikacin/kanamycin resistance genotypes was determined (Table 2), including identi-
fication of seven isolates with more than one streptomycin-resistance-determining
mutation (Table S4).
In comparing MIC data from Sensititre testing with known aminoglycoside resis-
tance genotypes, we evaluated the relationship between genotypic and phenotypic
resistance to streptomycin (Fig. 1A), amikacin (Fig. 1B), and kanamycin (Fig. S1). There
was a bell-shaped distribution (Fig. 1A) of isolates containing gidB mutations with
low-level streptomycin resistance (median MIC 4 g/ml; interquartile range [IQR], 2 to
4 g/ml) (Table 3). By critical concentration testing per the WHO-recommended guide-
lines, the majority of isolates with gidB mutations (76%, 70/92) were classified as
resistant to streptomycin. In contrast, high-level streptomycin resistance was observed
in isolates with either rrs (non-1400) or rpsL mutations, with median MIC 32 g/ml (IQR,
16 to 32 g/ml) and 32 g/ml (IQR, 16 to 32 g/ml), respectively. Three isolates with no
identifiable streptomycin mutations were noted to have high MICs to streptomycin
(MIC 16 to 32 g/ml), suggesting that additional streptomycin resistance mutations
remain to be discovered, but this could also be due to errors in phenotyping. Nearly
every isolate with high-level amikacin and kanamycin resistance contained an rrs 1400
mutation (Fig. 1B, Fig. S2).
When comparing the MIC of each isolate to streptomycin and amikacin, numerous
isolates had mismatched phenotypes, indicating that resistance to amikacin did not
confer resistance to streptomycin, and vice versa (Fig. 2). In particular, 29 isolates from
South Africa exhibited low-level streptomycin resistance (MIC 4 g/ml or 8 g/ml) and
concomitant high-level amikacin resistance (MIC 16 g/ml) (circled area, Fig. 2). These
findings suggest that use of streptomycin instead of amikacin would be the preferred
aminoglycoside for treatment of these isolates. The vast majority of isolates with this
phenotype (93%, 27/29) contained a gidB resistance genotype, and 100% (29/29)
contained an rrs 1400 mutation.
From the genomic data, we constructed a phylogeny to determine the interrelat-
edness of isolates with (i) low-level streptomycin resistance and (ii) concomitant
low-level streptomycin and high-level amikacin resistance in phenotypic testing (Fig. 3).
The 57 isolates with low-level streptomycin resistance were distributed throughout the
phylogeny. The majority (25/29, 86%) of South African isolates with low-level strepto-
mycin and high-level amikacin resistance belonged to the Tugela Ferry XDR clone,
which was responsible for epidemic XDR in the region in the early 2000s (13). However,
there were four isolates outside this cluster, indicating that this phenomenon was not
unique to this clone.
To determine whether the phenomenon of low-level streptomycin and high-level
amikacin resistance occurred outside South Africa, we analyzed our large data set of
5,310 M. tuberculosis isolates from 43 countries (14). Within this data set, 257 isolates
contained mutations for resistance to all four drugs that define XDR (rifampin, isoniazid,
TABLE 2 Distribution of co-occurring genotypic resistances to streptomycin and amikacin/
kanamycin in a South African data seta
Streptomycin genotype
Amikacin/kanamycin genotype
WT rrs 1400 eis promoter Total
WT 67 2 2 71
rpsL 33 2 0 35
rrs (non-1400) 8 5 0 13
gidB 44 41b 0 85
Total 152 50 2 204
aOf note, 7 isolates were identified to contain more than one streptomycin resistance mutation, as described
in Table S4 in the supplemental material.
bThe boldface type indicates the number of isolates with co-occurrence of gidB and rrs 1400 mutations that
confer low-level streptomycin and high-level amikacin resistance.
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ofloxacin, and amikacin). As phenotypic data were not available for this data set, we
used co-occurrence of a gidB resistance mutation and rrs 1400 mutation as a genotypic
predictor of this combination of low-level streptomycin resistance and high-level
amikacin resistance (Fig. 4). We identified 378 unique isolates with gidB mutations,
including 95 isolates with co-occurrence of gidB mutations and rrs 1400 mutation (Table
S5). All 95 isolates contained resistance-conferring mutations to both isoniazid and
rifampin (MDR genotype) in addition to resistance to either ofloxacin or kanamycin
(pre-XDR), and 81/95 of these isolates were XDR. Of the 257 XDR isolates in the
5,310-isolate data set, 81 (31.5%) of the XDR isolates contained this gidB-rrs 1400
FIG 1 Clinical strains of M. tuberculosis were observed to have a range of susceptibility to aminoglyco-
sides, mediated by resistance genotype. A total of 211 isolates of M. tuberculosis from South Africa
underwent MIC determination and aminoglycoside resistance genotyping to identify mutations that
confer resistance to streptomycin or amikacin, respectively. (A) Streptomycin MIC testing revealed a
bell-shaped curve distribution of gidB strains with low-level streptomycin resistance, whereas strains
containing rrs (non-1400) or rpsL mutations had higher resistance. Of note, three isolates containing
resistance elements in both gidB and rpsL were included among the rpsL isolates. (B) Amikacin MIC
testing revealed high-level resistance among strains containing the rrs 1400 mutation. Kanamycin MIC
results mirrored that of amikacin (Fig. S1 in the supplemental material).
TABLE 3 gidB mutations confer low-level streptomycin resistance, whereas rrs and rpsL
mutations confer high-level resistance
Streptomycin genotype Median MIC to streptomycin in g/ml (IQR)a
WT 1 (0.5–2)
gidB 4 (2–4)
rrs (non-1400) 32 (16–32)
rpsL 32 (32–32)
aFor each streptomycin resistance genotype, median MIC to streptomycin and interquartile range (IQR) is
listed.
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combination, indicating frequent occurrence in global XDR-TB. The majority of isolates
with the gidB-rrs 1400 pattern were LAM4 and likely members of the Tugela Ferry XDR
clade. However, there were nine other spoligotypes with isolates containing this
pattern, indicating multiple independent evolutionary events. Beyond South Africa,
isolates with this resistance pattern were also identified in Belarus, China, Iran, Portugal,
Romania, South Korea, and Sweden, indicating that this phenomenon of streptomycin-
low and amikacin-high resistance is of global importance for management of drug-
resistant TB.
DISCUSSION
In both a South African and a global data set, significant numbers of M. tuberculosis
isolates contained mutations associated with concomitant low-level streptomycin re-
sistance and high-level amikacin resistance. Current guidelines that recommend only
limited use of streptomycin (10) may be unwittingly withholding a potentially lifesav-
ing, inexpensive, and available drug from certain patients with drug-resistant TB.
Similarly, current WHO-endorsed laboratory procedures for performing phenotypic DST
to streptomycin by critical concentration may obscure the potential utility of strepto-
mycin by not distinguishing between high and low-level resistance.
Given additional newer agents with excellent activity against drug-resistant TB, such
as bedaquiline, the updated 2019 WHO guidelines limit use of aminoglycosides (10).
Kanamycin is no longer recommended in the treatment of drug-resistant TB patients on
longer regimens. Amikacin is now the preferred aminoglycoside, and its use is limited
to adults on longer regimens in situations in which DST results confirm susceptibility
and for whom high-quality audiometry testing for hearing loss can be performed.
Streptomycin use is recommended only when amikacin is not available, and again in
situations when DST results confirm susceptibility and in whom safety monitoring can
be ensured.
While treatment-related ototoxicity and nephrotoxicity are well established, strep-
tomycin could still hold therapeutic potential for individuals with drug-resistant TB
harboring isolates with low-level streptomycin resistance. If an aminoglycoside is being
considered for inclusion in a drug-resistant TB regimen, if the rrs 1400 mutation is
present, which confers high-level resistance to amikacin, than we recommend selection
of streptomycin, even in the face of low-level resistance, such as that conferred by gidB.
To our knowledge, clinical outcomes for individuals harboring isolates with low-level
streptomycin resistance mediated by gidB and treated with a streptomycin-containing
regimen have not been assessed. An expanded role for streptomycin in drug-resistant
FIG 2 Significant numbers of M. tuberculosis isolates exhibit concomitant low-level streptomycin resis-
tance and high-level amikacin resistance. Isolates are represented by streptomycin genotype (see key)
and plotted as a function of the relative phenotypic resistance to both amikacin and streptomycin. The
red dotted circle indicates the 29 isolates with concomitant low-level streptomycin resistance and
high-level amikacin resistance.
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TB may also increase risk of adverse events related to drug toxicity. Ensuring safety of
a streptomycin-based regimen would necessitate implementation of monitoring pro-
cedures, including audiometry and measurements of renal function, which constitute
an additional burden— especially for resource-limited settings.
In South Africa, due to a clonal outbreak of XDR-TB in Tugela Ferry, a large fraction
of circulating XDR-TB isolates contain an 130-bp deletion in gidB that confers low-level
streptomycin resistance and an rrs 1400 mutation that confers high-level cross-
resistance to amikacin, kanamycin, and capreomycin (15, 16). In a recent long-term
cohort study of XDR-TB treatment outcomes in South Africa, only 1% of patients were
treated with streptomycin, whereas 98% received capreomycin (17). As treatment
FIG 3 Concomitant low-level streptomycin and high-level amikacin phenotypic resistance in South African M.
tuberculosis isolates across the phylogeny. Midpoint rooted maximum-likelihood phylogeny of 211 M. tuberculosis
isolates, containing representatives of four of the seven known M. tuberculosis lineages. Phenotypic MDR and XDR
are indicated by black and white boxes at the tip of each leaf node. The levels of phenotypic resistance to
streptomycin (low, MIC 4 to 8 g/ml; high, MIC 16 g/ml) and amikacin (low, MIC 4 to 8 g/ml; high, MIC 16 g/
ml) are indicated by box color, per the key. Strains with concomitant low-level streptomycin resistance and
high-level amikacin resistance are indicated in red. While the majority of isolates with low-level streptomycin
resistance and high-level amikacin resistance pertained to the Tugela Ferry XDR outbreak clone, four examples
were observed outside the outbreak clone, indicating that this was not an isolated evolutionary event.
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outcomes for XDR-TB in South Africa were notoriously abysmal (17), including strep-
tomycin may prove useful for patients in whom new drugs are not available because
of resistance or contraindications.
Current WHO-endorsed laboratory procedures for performing phenotypic DST to
streptomycin by critical concentration fail to provide key information relevant to
streptomycin inclusion in a regimen for drug-resistant TB. The MIC distribution for
isolates containing gidB mutations straddles the WHO-recommended critical concen-
tration of 2 g/ml (Fig. 1A). This modest increase in MIC among isolates containing gidB
mutations in comparison to wild-type isolates likely contributes to inconsistencies in
testing. Isolates containing gidB mutations are frequently misclassified in terms of their
susceptibility to streptomycin on critical concentration testing (as occurred in 24% of
FIG 4 Concomitant low-level streptomycin and high-level amikacin genotypic resistance evolved repeatedly in a
global data set of M. tuberculosis. Midpoint rooted maximum-likelihood phylogeny of 5,310 M. tuberculosis strains
from a global data set containing representatives of all seven known M. tuberculosis lineages. The presence and
levels of genotypic resistance to streptomycin (low, gidB; high, rrs [non-1400] and rpsL) and amikacin (high, rrs 1400)
are indicated by box color near the leaf nodes. Ninety-five isolates with genotypic mutations predicted to confer
both low-level streptomycin resistance and high-level amikacin resistance (gidB-rrs 1400) are indicated in red.
Concomitant low-level streptomycin resistance and high-level amikacin resistance occurred across the phylogeny,
indicating that this phenomenon is of global relevance for TB control.
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isolates in this study). As critical concentration testing is typically performed only at a
single concentration, isolates with low-level streptomycin resistance—which may po-
tentially be treated successfully with streptomycin— cannot be distinguished from
those with high-level resistance. Similarly, wild-type strains that do not contain geno-
types predicted to confer resistance to streptomycin can exhibit low-level streptomycin
resistance that is above the critical concentration threshold (as seen in four South
African isolates in this study), which may result in withholding a potentially useful drug.
The WHO-recommended critical concentration for streptomycin in M. tuberculosis is
based on weak scientific evidence (12). The upper limit of wild-type MIC distribution,
termed the epidemiological cutoff value (ECOFF), for streptomycin is 2 g/ml (18). That
this is the same value as the critical concentration in DST reflects the lack of clinical and
pharmacokinetic/pharmacodynamic data to inform a more practical selection of a
critical concentration. Potential strategies to address this issue include: (i) raising the
streptomycin critical concentration; (ii) adding a second streptomycin drug concentra-
tion to traditional critical concentration testing (e.g., test at both 2 g/ml and 8 g/ml
to disambiguate between low-level and high-level streptomycin resistance); (iii) per-
forming additional reflex testing when an isolate is identified by traditional critical
concentration DST to be resistant to both streptomycin and kanamycin (e.g., more
detailed phenotypic analysis or streptomycin resistance genotype determination); or
(iv) forgoing critical concentration testing in all forms and instead expanding genotypic
aminoglycoside resistance testing.
Recent efforts to expand the complement of drug resistance mutation panels
included on rapid molecular TB diagnostics have not included streptomycin (19).
Whole-genome sequencing (WGS) studies of clinical isolates of M. tuberculosis have
demonstrated that the majority (92% to 95%) of streptomycin-resistant isolates can be
explained by known mutations (20, 21). Thus, omitting streptomycin resistance deter-
minants from rapid drug resistance panels is a missed opportunity to both identify and
grade streptomycin resistance relative to amikacin resistance. One potential reason for
this exclusion is mutations in gidB can occur anywhere in the gene, where they cause
frameshift, nonsense, or deletion mutations. Thus, they are difficult to identify with
current SNP-based diagnostics and instead require whole-gene-based strategies, such
as high-resolution melt analysis (22) or rapid WGS.
It is important to address several limitations of this study. MIC determination was
performed with Sensititre, which is not the gold standard for M. tuberculosis DST.
However, prior investigation comparing Sensititre with traditional methods have shown
excellent concordance for aminoglycoside testing (23, 24). In addition, phenotyped
isolates derived only from South Africa, and the population structure contained clonal
XDR isolates from the Tugela Ferry epidemic. However, the phenomenon of genotypic
resistance conferring low-level streptomycin and high-level amikacin resistance was
also seen outside this clone. Thus, this observation carries implications for M. tubercu-
losis treatment in other settings.
Our findings suggest that current critical concentration methods for streptomycin
resistance determination and the design of molecular diagnostics for resistance may
need to be revisited for improved categorization of isolates harboring gidB mutations,
which confer low-level streptomycin resistance. In the context of limited therapeutic
options for drug-resistant M. tuberculosis, our results show the potential utility of
streptomycin, even for isolates observed to have low-level resistance from gidB muta-
tions.
MATERIALS AND METHODS
Clinical isolates. We selected for inclusion a random subset of 211 clinical isolates of susceptible and
drug-resistant M. tuberculosis from South Africa from our larger sequenced strain set (15).
Drug susceptibility testing by critical concentration. As previously described (15), DST was
performed prospectively by critical concentration on Middlebrook 7H11 using the WHO-recommended
drug concentrations for streptomycin (2.0 g/ml) and kanamycin (6.0 g/ml). Amikacin critical concen-
tration was not performed, as isolates with acquired resistance to amikacin essentially always have
resistance to kanamycin (12).
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MIC determination. MIC determination for three aminoglycosides (amikacin, kanamycin, and strep-
tomycin) was performed using MycoTB Sensititre plates (TREK Diagnostic Systems), per the manufac-
turer’s instructions. The lowest concentration of drug that did not show visible growth was recorded as
the MIC to the respective drug.
Whole-genome sequencing and analysis. Whole-genome sequencing (WGS) and analysis were
performed as previously described (15). Genotypic resistance to streptomycin, amikacin, and kanamycin
was defined as identification of polymorphisms that are known to be associated with drug resistance, per
the refined genotypic resistance definition in Desjardins and Cohen et al. (20) (Table S1). Isolates
belonging to the Tugela Ferry XDR clone were identified by phylogenetic clustering with the reference
isolates KZN605, collected during the epidemic, as well as the presence of canonical drug-resistance
mutations (15). SNP calls from Cohen et al. were used (15). RAxML version 7.3.0 (25) was used to construct
a phylogenetic tree from concatenated SNPs, with 1,000 bootstrap replicates.
Data availability. All sequencing data can be found in the Sequence Read Archive NCBI umbrella
project identifier PRJNA183624.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.
SUPPLEMENTAL FILE 2, XLSX file, 0.04 MB.
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